Literature DB >> 7776980

Characterization of the sequences of the human CYP19 (aromatase) gene that mediate regulation by glucocorticoids in adipose stromal cells and fetal hepatocytes.

Y Zhao1, C R Mendelson, E R Simpson.   

Abstract

The biosynthesis of estrogens is catalyzed by aromatase P450 (P450arom), the product of the CYP19 gene. The tissue-specific expression of the CYP19 gene is regulated by means of tissue-specific promoters through the use of alternative splicing mechanisms. Thus, transcripts containing various 5'-untranslated termini are present in human placenta and other fetal tissues, ovary, brain, and adipose stromal cells. Sequence corresponding to untranslated exon 1.4 is present in 5'-termini of transcripts expressed in adipose tissue and fetal liver, as well as adipose stromal cells in primary culture in the presence of dexamethasone and fetal calf serum (FCS). Identification of hormone-responsive, tissue-specific promoter regions, as well as growth factor-response elements upstream of exon 1.4, may provide insight into the regulation of estrogen biosynthesis in adipose tissue, which is implicated in the development of breast and endometrial cancer. The goals of the present study were to define the 1.4 promoter region with respect to the start of transcription and to characterize the region(s) responsible for conferring glucocorticoid responsiveness on aromatase expression. The transcription initiation site was identified by means of primer extension and S1 nuclease protection analyses. No TATA-like sequence was evident upstream of this site. Various deletion mutations of the upstream flanking region of exon 1.4 and including part of exon 1.4 were made using polymerase chain reaction or restriction enzyme digestion. The genomic fragments were fused upstream of the chloramphenicol acetyltransferase (CAT) reporter gene. These constructs were transfected into adipose stromal cells and fetal hepatocytes in primary culture in medium containing FCS with or without dexamethasone. The -560/+10 base pair (bp) construct expressed CAT activity after a putative silencer element was deleted, and expression was induced by dexamethasone about 3-fold. Transfection of the -330/+170 bp construct, which contains an upstream glucocorticoid response element (GRE) as well as an Sp1-like sequence in untranslated exon 1.4, resulted in an 8-fold stimulation of expression of CAT activity by dexamethasone. The upstream GRE as well as the Sp1-like sequence in untranslated exon 1.4 were mutated separately, and together, to further confirm whether the GRE or Sp1 binding site play a role in the regulation of promoter 1.4-driven transcription. Mutation of either the GRE or Sp1 binding site, or both, in the -330/+170 bp construct, resulted in loss of dexamethasone-induced CAT reporter gene expression.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7776980     DOI: 10.1210/mend.9.3.7776980

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  29 in total

1.  The gene for aromatase, a rate-limiting enzyme for local estrogen biosynthesis, is a downstream target gene of Runx2 in skeletal tissues.

Authors:  Jae-Hwan Jeong; Youn-Kwan Jung; Hyo-Jin Kim; Jung-Sook Jin; Hyun-Nam Kim; Sang-Min Kang; Shin-Yoon Kim; Andre J van Wijnen; Janet L Stein; Jane B Lian; Gary S Stein; Shigeaki Kato; Je-Yong Choi
Journal:  Mol Cell Biol       Date:  2010-03-15       Impact factor: 4.272

Review 2.  Structural and functional characterization of aromatase, estrogen receptor, and their genes in endocrine-responsive and -resistant breast cancer cells.

Authors:  Hei Jason Chan; Karineh Petrossian; Shiuan Chen
Journal:  J Steroid Biochem Mol Biol       Date:  2015-08-13       Impact factor: 4.292

3.  Systemic Estrone Production and Injury-Induced Sex Hormone Steroidogenesis after Severe Traumatic Brain Injury: A Prognostic Indicator of Traumatic Brain Injury-Related Mortality.

Authors:  Milap V Rakholia; Raj G Kumar; Byung-Mo Oh; Prerna R Ranganathan; Sarah L Berga; Patrick M Kochanek; Amy K Wagner
Journal:  J Neurotrauma       Date:  2018-08-24       Impact factor: 5.269

Review 4.  Aromatase inhibitors and inactivators for breast cancer therapy.

Authors:  Per E Lønning
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 5.  Biology of aromatase in the mammary gland.

Authors:  E R Simpson
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-07       Impact factor: 2.673

6.  Rs1008805 polymorphism of CYP19A1 gene is associated with the efficacy of hormone therapy in stage I-II and operable stage III breast cancer.

Authors:  Xiying Shao; Lei Luo; Yong Guo; Xiaohong Xu; Dehou Deng; Jianguo Feng; Yuheng Ding; Hanzhou Mou; Ping Huang; Lei Shi; Yuan Huang; Weiwu Ye; Caijin Lou; Zhanhong Chen; Yabing Zheng; Xiaojia Wang
Journal:  Oncol Lett       Date:  2017-09-18       Impact factor: 2.967

7.  Association of genetic polymorphisms in CYP19A1 and blood levels of sex hormones among postmenopausal Chinese women.

Authors:  Hui Cai; Xiao Ou Shu; Kathleen M Egan; Qiuyin Cai; Ji-Rong Long; Yu-Tang Gao; Wei Zheng
Journal:  Pharmacogenet Genomics       Date:  2008-08       Impact factor: 2.089

Review 8.  Aromatase expression and regulation in breast and endometrial cancer.

Authors:  Hong Zhao; Ling Zhou; Anna Junjie Shangguan; Serdar E Bulun
Journal:  J Mol Endocrinol       Date:  2016-04-11       Impact factor: 5.098

9.  In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer.

Authors:  Anne E Lykkesfeldt; Katrine L Henriksen; Birgitte B Rasmussen; Hironobu Sasano; Dean B Evans; Susanne Møller; Bent Ejlertsen; Henning T Mouridsen
Journal:  BMC Cancer       Date:  2009-06-16       Impact factor: 4.430

10.  Tissue-specific increases in 11beta-hydroxysteroid dehydrogenase type 1 in normal weight postmenopausal women.

Authors:  Therése Andersson; Kotryna Simonyte; Ruth Andrew; Magnus Strand; Jonas Burén; Brian R Walker; Cecilia Mattsson; Tommy Olsson
Journal:  PLoS One       Date:  2009-12-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.